Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP (Q84347972)
Jump to navigation
Jump to search
scientific article published on 03 June 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP |
scientific article published on 03 June 2010 |
Statements
Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP (English)
John F DiJoseph
Maureen M Dougher
Deborah Y Evans
Bin-Bing Zhou